Hepatoprotective properties of potentiated antibodies to cholecystokinin.
Ultralow doses of antibodies to cholecystokinin prevented hepatocyte death, delayed the formation of the connective tissue, and normalized plasma of liver enzyme in rats with experimental acute and chronic toxic hepatitis.